Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Govt Unveils Draft Honebuto Paper for 2021, Cabinet OK Expected after Party Tweaks
The Japanese government presented a draft of this year’s Basic Policy for Economic and Fiscal Management and Reform to its key advisory panel on June 9. The paper, dubbed honebuto, is due to be adopted by the Cabinet later this…
To read the full story
Related Article
- Japan OKs 2021 Fiscal Policy Blueprint, Vows Transparency in Drug Pricing
June 21, 2021
- Honebuto Text to Add Line for “Transparency and Predictability” of Drug Pricing System
June 16, 2021
- LDP Flags 80% Generic Target for All Prefectures: Honebuto Debate
June 11, 2021
- Japan Aims for 80% Generic Share in All Prefectures by FY2023-End: Honebuto Draft
June 9, 2021
REGULATORY
- MHLW Panel Deems 4 More “Drug Loss” Products as High-Need
May 27, 2026
- LDP Panel OKs Immunization Act Bill Aimed at Beyfortus NIP Use
May 27, 2026
- Japan Selects JN.1 Substrains for COVID Vaccines in 2026-2027 Season
May 27, 2026
- Ex-Minister Kato Preparing Parliamentary Group on Diabetes Issues
May 27, 2026
- LDP Lawmakers’ League Urges Economic Efficiency in Drug Use
May 27, 2026
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…